Currently Viewing:
North American Neuroendocrine Tumor Society Symposium 2018
Measuring Quality of Life Among Patients With Neuroendocrine Tumors
October 05, 2018
Analysis Demonstrates Effectiveness, Patient Satisfaction With Lanreotide in GEP-NETs
October 05, 2018
Dr Heloisa Soares Discusses the Roles of Somatostatin Analogs in GEP-NETs
October 05, 2018
Examining the Benefits of Integrative Oncology, Nutrition in NETs
October 05, 2018
Debating Best First-Line Treatment in Well-Differentiated G3 NENs
October 06, 2018
Merkel Cell Carcinoma in the United States: Prognostics and Treatment Options
October 06, 2018
Dr Scott Paulson on Current Challenges in the NETs Treatment Landscape
October 06, 2018
Sequencing of Lanreotide Can Improve Outcomes in Patients With Advanced GEP-NETs
October 06, 2018
Dr Thorvardur Halfdanarson Outlines New, Exciting Developments in Treatment of NETs
October 07, 2018
An Update on Lung NET Guidelines
October 07, 2018
A Comprehensive Look at Updates, Developments in NETs
October 07, 2018
Research at NANETS Cites Value of Genetic Testing in Neuroendocrine Tumors
October 07, 2018
Currently Reading
Dr Heloisa Soares on the Importance of Multidisciplinary Care, Patient Engagement in NETs
October 17, 2018
Dr Thorvardur Halfdanarson on if He Thinks There's a Future For Immunotherapy in NETs
October 23, 2018
Dr Heloisa Soares on Barriers to Achieving Positive Outcomes in NETs, What's in Store for the Future
November 01, 2018
Dr Scott Paulson: Role of Somatostatin Analogs, Biomarkers in Treatment of GEP-NETs
November 06, 2018
Dr Thorvardur Halfdanarson on Diagnostics in NETs
November 08, 2018
Dr Thorvardur Halfdanarson: Access Is a Big Management Challenge in NETs
November 20, 2018
Dr Thorvardur Halfdanarson Discusses Lack of Risk Factors, Biomarkers in NETs
December 04, 2018

Dr Heloisa Soares on the Importance of Multidisciplinary Care, Patient Engagement in NETs

Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque, discusses the importance of treating neuroendocrine tumors with a multidisciplinary team, as well as the importance of engaging patients and their families in their care.


Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque, discusses the importance of treating neuroendocrine tumors with a multidisciplinary team, as well as the importance of engaging patients and their families in their care.

Transcript

Why is it important to treat neuroendocrine tumors with a multidisciplinary team?


I cannot emphasize enough how important it is to have a multidisciplinary team for neuroendocrine tumors (NETs). You have to have a NET-focused pathologist to review the slides of the patient, because often, the diagnosis can change slightly. When we have a pathologist reviewing that that specializes in NETs, then you have to have a good radiologist helping to read the films.

Then, you have to have your surgeon or surgical oncologist looking and evaluating the patient with you, because even in the setting of stage 4 disease or metastatic disease, we can still offer surgery to these patients in many occasions. They surgeries can even be a curative intent in putting the patients in remission for a very long time, or it could be offered to improve the quality of life, because some of these patients are so symptomatic that the bulking of the disease can make wonders for the quality of life.

We also have to have a nuclear medicine physician with us because now with the upcoming use of peptide receptor radionuclide therapy, you know, our colleagues from nuclear medicine are extremely essential for the treatment of NETs. We have to have the help our endocrinologist to help with some of the issues that come with having a NET patient. I haven’t even mentioned the fact that we need the help of the gastroenterologist to diagnosis the disease, because sometimes we have to do 2 endoscopy procedures, but also with helping managing some of the most challenging issues of these patients, including diarrhea, for example.

So, these are just a few examples of how a patient with NETs should be taken care of by a multidisciplinary team.

How important is it to engage patients and their families in their care so that they understand their treatment and their diagnosis?

So, it’s very important to educate patients and their families in terms of the new diagnosis of NETs. When patients come to the clinic to me, I typically explain what a NET is. I try to make the comparison, to some extent, I compare the Steve Jobs pancreatic cancer versus the Patrick Swayze pancreatic cancer. That gives a sort of visual understanding of the difference between both diseases.

I try to explain the natural history of the disease as much as the capability of the patient to understand the differences. And then I also redirect patients to reliable sources of information that we have on the internet, from the different NET organization that we have with the Carcinoid Foundation, we have the Healing NET Foundation. The NET Research Foundation also has some information for patients. I think all of these are very important. There’s also amazing supportive group organizations out there. They are extremely reliable and supportive to patients, so I tend to direct my patients to these type of organizations as well.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up